Skip to search formSkip to main contentSkip to account menu

SR 45023A

Known as: SR45023A, SR-45023A (Apomine), Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl) Ester 
National Institutes of Health

Related topics

Related topics

2 relations
SK&F 99085

Broader (1)

apomine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
SummaryMetastatic melanoma continues to be a very difficult disease to treat. Options are limited and often have very little… 
2001
2001
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
PURPOSE To study the human pharmacokinetics and in vitro cytotoxicity of Apomine, an p.o. administered, nonmyelosuppressive agent… 
2000
2000
The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol.
Apomine (SR-45023A) is a new antineoplastic compound which is currently in clinical trials and representative of the family of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)